Tianjin Zhong Xin Pharmaceutical Group Corporation has reported earnings of RMB213 million ($43.5 million) for its 1QFY2021 ended March, up 25% y-o-y. The higher earnings follow an increase in revenue for the period, which climbed 10% y-o-y from RMB1.65 billion to RMB1.83 billion on the back of high...

Tianjin Zhong Xin Pharmaceutical Group Corporation has recorded earnings of RMB661.7 million ($135.8 million) or 0.86 RMB cents per share for the FY2020 ended December, 6% higher than earnings of RMB625.6 million a year ago. FY2020 revenue fell 6% y-o-y to RMB6.60 billion largely due to lower revenu...

THE following companies saw new developments that may affect trading of their securities on Monday:

Tianjin Zhong Xin Pharmaceutical Group says Jinhushen Biological Medical Science and Technology has completed its acquisition in its controlling shareholder, Tianjin Pharmaceutical Holdings (TPH) on March 26. Jinhushen, on Dec 19, 2020, entered into a sale and purchase agreement (SPA) with Tianjin B...

FOLLOWING a transfer of a two-thirds ownership in Chinese conglomerate Tianjin Pharmaceutical Holdings (TPH) to a third party, a "chain offer" for the remaining shares of Tianjin Zhong Xin Pharmaceutical Group on both the Singapore and Shanghai bourses that are not held by offeror ...

Tianjin Zhong Xin Pharmaceutical Group announced on Dec 20 that Jinhushen Biological Medical Science and Technology has acquired a 67% stake in its controlling shareholder, Tianjin Pharmaceutical Holdings (TPH). See: Tianjin Zhong Xin Pharmaceutical triggers SGX query as shares increase by over...

THE following companies saw new developments that may affect trading of their securities on Monday:

TIANJIN Zhong Xin Pharmaceutical Group announced on Sunday that Jinhushen Biological Medical Science and Technology will be acquiring a 67 per cent stake in its controlling shareholder Tianjin Pharmaceutical Holdings for an undisclosed sum.

A PROPOSED acquisition of shares in Tianjin Zhong Xin Pharmaceutical Group by its controlling shareholder may have been behind the price surge in shares of the company on Thursday.

A PROPOSED acquisition of shares in Tianjin Zhong Xin Pharmaceutical Group by its controlling shareholder may have been behind the price surge in shares of the company on Thursday.